Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators

  title={Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators},
  author={Mark D. Berry},
  journal={Journal of Neurochemistry},
  • M. D. Berry
  • Published 1 July 2004
  • Biology
  • Journal of Neurochemistry
The presence of the so‐called trace amines 2‐phenylethylamine, m‐tyramine, p‐tyramine, m‐octopamine, p‐octopamine and tryptamine in the mammalian central nervous system has been known for several decades. Despite much initial interest, these amines have largely been thought of as little more than metabolic by‐products. The recent description of a family of mammalian trace amine receptors has, however, seen a resurgence of interest in the physiological role of this class of compounds. Although… 
The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain
Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons
Three important new aspects of TAs action have recently emerged: inhibition of firing due to increased release of dopamine; reduction of D2 and GABAB receptor-mediated inhibitory responses (excitatory effects due to disinhibition); and a direct activation of GIRK channels by TA1 receptors which produce cell membrane hyperpolarization.
Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications
TAAR1 is uniquely positioned to exert direct control over DA and 5-HT neuronal firing and release, which has profound implications for understanding the pathophysiology of, and therefore designing more efficacious therapeutic interventions for, a range of neuropsychiatric disorders that involve aminergic dysregulation.
The vascular effects of trace amines and amphetamines.
  • K. Broadley
  • Biology, Chemistry
    Pharmacology & therapeutics
  • 2010
Trace amine‐associated receptors and their ligands
Pharmacological investigations in vitro show that many TAAR subtypes may not respond to p‐tyramine, β‐phenylethylamine, tryptamine or octopamine, suggesting the existence of additional endogenous ligands, and genetic linkage studies show a significant association between the TAAR gene family locus and susceptibility to schizophrenia or bipolar affective disorder.
Trace Amine-Associated Receptors as Emerging Therapeutic Targets
It is expected that further characterization of the functional roles and biochemical properties of TAARs and identification of endogenous and exogenous ligands will eventually promote these receptors as an attractive class of targets to correct monoaminergic processes that could be dysfunctional in a host of disorders of brain and periphery.
Metabolic recruitment of spinal locomotion: intracellular neuromodulation by trace amines and their receptors
  • S. Hochman
  • Biology, Chemistry
    Neural regeneration research
  • 2015
A large earlier literature asserted their role as endogenous neuromodulators of monoaminergic excitability and neurotransmission, challenging the more conventional view of the TAs as metabolic byproducts that interfere with classical monoamine modulatory functions.


Trace amines: Identification of a family of mammalian G protein-coupled receptors
Using a degenerate PCR approach, 15 G protein-coupled receptors (GPCR) from human and rodent tissues are identified and it is demonstrated that two of these receptors bind and/or are activated by trace amines.
Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor.
The discovery and pharmacological characterization of a rat G protein-coupled receptor that stimulates the production of cAMP when exposed to the trace amines p-tyramine, beta-phenethylamine, tryptamine, and octopamine and the discovery that amphetamines are potent rTAR1 agonists suggests that the effects of these widely used drugs may be mediated in part by this receptor as well as their previously characterized targets, the neurotransmitter transporter proteins.
Brain Trace Amines: Mapping Studies and Effects of Mesencephalic Lesions
The brain trace amine concentration has been estimated by different research groups and extends over a wide range of values; the general tendency, however, has been towards the confirmation of the
Phenylethylamine in the CNS: effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission.
Following iontophoresis PE has been shown to exhibit indirect sympathomimetic effects but in addition when applied at low currents concurrently with DA or NA it causes post synaptically a substantial potentiation in the actions of the latter amines.
Evidence for the presence of m-tyramine, p-tyramine, tryptamine, and phenylethylamine in the rat brain and several areas of the human brain.
Postmortem changes in human brain amines are discussed in relation to those occurring postmortem in the rat brain, in which phenylethylamine, p-tyramine, and tryptamine have been shown to increase to levels greater than those prevailing in vivo.
The effects of administration of monoamine oxidase‐B inhibitors on rat striatal neurone responses to dopamine
The results suggest that PE can act as a neuromodulator of dopaminergic responses and that MAO‐B inhibitors may potentiate neuronal responses to dopamine via the indirect mechanism of elevation of PE following MAO'B inhibition.
Elusive amines and primary headaches: historical background and prospectives
Evidence supporting a role of trace amines in the pathogenesis of migraine and cluster headache is summarized and a historical perspective is outlined and new opportunities for pharmacological strategies acting on these receptors are outlined.
Dose‐response and time‐response studies have been carried out with clorgyline and deprenyl, inhibitors which preferentially inhibit the A and B forms of MAO, respectively, and with tranylcypromine and phenylethylhydrazine, which are used clinically in the treatment of depression.